NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Saturday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY opened at $0.62 on Friday. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The company has a 50 day simple moving average of $0.63 and a two-hundred day simple moving average of $0.89. The company has a market capitalization of $3.03 million, a PE ratio of -0.01 and a beta of 0.65.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.